Literature DB >> 7636268

Complement membrane attack complex, perforin, and bacterial exotoxins induce in K562 cells calcium-dependent cross-protection from lysis.

Y Reiter1, A Ciobotariu, J Jones, B P Morgan, Z Fishelson.   

Abstract

The complement membrane attack complex (MAC), the cytolytic granule protein of cytotoxic lymphocytes perforin, the streptococcal exotoxin streptolysin O (SLO), and the bee venom polypeptide melittin utilize a similar mechanism to incorporate into cell membranes, induce a Ca2+ influx and a rise in intracellular Ca2+ concentration, and produce cell lysis. At sublytic concentrations, these proteins trigger several cellular activities, including protein phosphorylation and synthesis. We have recently demonstrated that human leukemic cells treated with sublytic doses of human complement become more resistant to lytic complement doses. The study has now been extended to include three other pore-formers: murine perforin, SLO and melittin. As shown here, sublytic MAC induces in the K562 human erythroleukemic cells protection from lytic perforin, and vice versa, sublytic perforin induces protection from complement. Also, sublytic SLO and melittin increase resistance of K562 cells to lytic complement and perforin doses. The capacity of Ca2+ ionophores to induce resistance to the lytic proteins has been examined. Exposure of K562 cells to sublytic concentrations of ionomycin or A23187 for 1 h at 37 degrees C confers on them resistance to complement- and perforin-mediated lysis. The protective effects of the ionophores can be abrogated by chelation of extracellular Ca2+ and by inhibition of RNA or protein synthesis in the cells. These results indicate the following: 1) nucleated cells exposed to sublytic complement MAC, perforin, SLO, or melittin may become resistant to the four pore-formers. Physiologically, this may be regarded as an immunologic tachyphylaxis. 2) Ca2+ influx induced by these pore-formers is an essential and sufficient factor to produce this tachyphylaxis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7636268

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  16 in total

1.  Involvement of the ERK mitogen-activated protein kinase in cell resistance to complement-mediated lysis.

Authors:  S Kraus; R Seger; Z Fishelson
Journal:  Clin Exp Immunol       Date:  2001-03       Impact factor: 4.330

2.  Complement resistance of human carcinoma cells depends on membrane regulatory proteins, protein kinases and sialic acid.

Authors:  N Donin; K Jurianz; L Ziporen; S Schultz; M Kirschfink; Z Fishelson
Journal:  Clin Exp Immunol       Date:  2003-02       Impact factor: 4.330

3.  Sublytic complement protects prostate cancer cells from tumour necrosis factor-α-induced cell death.

Authors:  L Liu; W Li; Z Li; M Kirschfink
Journal:  Clin Exp Immunol       Date:  2012-08       Impact factor: 4.330

4.  Mechanisms of complement resistance induced by non-lethal complement attack and by growth arrest.

Authors:  K J Marchbank; C W van den Berg; B P Morgan
Journal:  Immunology       Date:  1997-04       Impact factor: 7.397

Review 5.  Antigenic modulation and rituximab resistance.

Authors:  Ronald P Taylor; Margaret A Lindorfer
Journal:  Semin Hematol       Date:  2010-04       Impact factor: 3.851

Review 6.  Escaping from rejection.

Authors:  Raymond J Lynch; Jeffrey L Platt
Journal:  Transplantation       Date:  2009-12-15       Impact factor: 4.939

7.  Retinal pigment epithelial cell death by the alternative complement cascade: role of membrane regulatory proteins, calcium, PKC, and oxidative stress.

Authors:  Ping Yang; Peter Baciu; Brittany C Parker Kerrigan; Menna Etheridge; Eric Sung; Brett A Toimil; Jacob E Berchuck; Glenn J Jaffe
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-05-06       Impact factor: 4.799

Review 8.  Accommodation in renal transplantation: unanswered questions.

Authors:  Raymond J Lynch; Jeffrey L Platt
Journal:  Curr Opin Organ Transplant       Date:  2010-08       Impact factor: 2.640

9.  Complement Inhibition: A Novel Form of Immunotherapy for Colon Cancer.

Authors:  Stephanie Downs-Canner; Deepa Magge; Roshni Ravindranathan; Mark E O'Malley; Lily Francis; Zuqiang Liu; Z Sheng Guo; Natasa Obermajer; David L Bartlett
Journal:  Ann Surg Oncol       Date:  2015-08-20       Impact factor: 5.344

Review 10.  Two-way traffic on the road to plasma membrane repair.

Authors:  Vincent Idone; Christina Tam; Norma W Andrews
Journal:  Trends Cell Biol       Date:  2008-10-09       Impact factor: 20.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.